Dublin-based Medtronic has announced the commercial launch of the IN.PACT Admiral Drug-Coated Balloon (DCB) in Japan.

IN.PACT Admiral DCB is a clinically proven, primary endovascular therapy that treats femoropopliteal disease, reduces interventions, and preserves future treatment options.

Last year, the Japanese Ministry of Health, Labor and Welfare (MHLW) granted approval for IN.PACT Admiral for the treatment of peripheral artery disease (PAD) in the upper leg specifically, in the thigh (superficial femoral arteries (SFA) and behind the knee (popliteal arteries).

This development follows the completion of a post-market clinical trial, which was conducted on 300 subjects.

-----------------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of en-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.